Alice Chen, M.D.
Head, Early Clinical Trials Development Division of Cancer Treatment and Diagnosis National Cancer Institute
Dr. Chen is the head of the Early Clinical Trials Development program in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute (NCI). She received her medical oncology training at Baylor College of Medicine and completed a Clinical Oncology and Regulatory Sciences Fellowship with the U.S. Federal Drug Administration and NCI. She is board-certified in internal medicine and medical oncology. Dr. Chen had served for 10 years as a medical officer in the Cancer Therapy Evaluation Program at NCI. She served as a primary and associate investigator in a broad spectrum of clinical trials ranging from phase 0 through phase 4. She directs the NCI’s Developmental Therapeutics Clinic which focuses on determining proof of concept, biomarkers and experimental trial designs in early drug development, working toward more successful confirmatory late phase trials. She is the primary investigator for Molecular Profiling-based Assignment of Cancer Therapeutics (NCI-MPACT) and co-primary investigator for the Molecular Analysis for Therapy Choice (NCI-MATCH), two of the NCI-sponsored Precision Medicine Initiative trials. She is the recipient of nine NIH Awards of Merit for her contribution to international relationships, adverse event reporting, CTCAE, PRO-CTCAE and NCI-MATCH.